Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

Journal Articles

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Alexander Coltoff, MD, Joseph G. Jurcic, MD, Peter Campbell, PharmD, BCOP, Daniel J. Lee, MD, Mark L Heaney, MD, Nicole Lamanna, MD, Todd L. Rosenblat, MD MS, Mark G. Frattini, MDPhD, George Vlad, PhD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-134237

Published: 2020

Journal Articles

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Blood (2020) 136 (Supplement 1): 13–15.

https://doi.org/10.1182/blood-2020-137232

Published: 2020

Journal Articles

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

Jacqueline S. Garcia, MD, Andrew H. Wei, Uma Borate, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Joseph G. Jurcic, MD, Meagan A. Jacoby, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Ilona Cunningham, MBBS, FRACP, FRCPA, Ying Zhou, PhD, Bo Tong, PhD, Leah Hogdal, PhD, Rajesh Kamalakar, MS, Jessica E. Hutti, PhD, Steve Kye, MD MPH, Guillermo Garcia-Manero, MD

Blood (2020) 136 (Supplement 1): 55–57.

https://doi.org/10.1182/blood-2020-139492

Published: 2020

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD

Blood (2019) 134 (Supplement_1): 3899.

https://doi.org/10.1182/blood-2019-130203

Published: 2019

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Blood (2018) 132 (Supplement 1): 1.

https://doi.org/10.1182/blood-2018-99-110805

Published: 2018

Journal Articles

Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 564.

https://doi.org/10.1182/blood-2018-99-110975

Published: 2018

Journal Articles

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, MD, Joseph G. Jurcic, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Raoul Tibes, MD PhD, Jason E. Hill, PhD, Matt Rosales, Erkut Bahceci, MD

Blood (2018) 132 (Supplement 1): 1458.

https://doi.org/10.1182/blood-2018-99-110971

Published: 2018

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Ehab L. Atallah, MD, Johnnie J. Orozco, MD PhD, Michael Craig, MD, Moshe Yair Levy, MD, Laura E. Finn, MD, Sharif S. Khan, MD, Alexander E. Perl, MD, Jae H. Park, MD, Gail J. Roboz, MD, William Tse, MD, Kebede H. Begna, MD, Raya Mawad, MD, David A. Rizzieri, MD, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2018) 132 (Supplement 1): 1457.

https://doi.org/10.1182/blood-2018-99-111951

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Blood (2017) 130 (Supplement 1): 2633.

https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633

Published: 2017

Journal Articles

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Laura E. Finn, MD, Moshe Levy, MD, Johnnie J. Orozco, MD PhD, Jae H. Park, MD, Ehab Atallah, MD, Michael Craig, MD, Alexander E. Perl, MD, David A. Scheinberg, MDPhD, Dragan Cicic, MD, Gregory Richard Bergonio, MSc, BSN, Mark S. Berger, MD, Joseph G. Jurcic, MD

Blood (2017) 130 (Supplement 1): 2638.

https://doi.org/10.1182/blood.V130.Suppl_1.2638.2638

Published: 2017

Journal Articles

Longitudinal Transcriptome Analysis of Myelodysplatic Syndrome Progression to Acute Myeloid Leukemia: Implications for Prognosis

Etienne De Clara, PhD, Abdullah Mahmood Ali, PhD, Jehanzeb Kayani, Christopher Szeto, PhD, Justin Golovato, Andrew Sedgewick, PhD, Joseph G. Jurcic, MD, Steve Benz, PhD, Shahrooz Rabizadeh, PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 3961.

https://doi.org/10.1182/blood.V130.Suppl_1.3961.3961

Published: 2017

Journal Articles

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Keith Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark J. Levis, MD, Tara L. Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, Chaofeng Liu, PhD MBA, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 722.

https://doi.org/10.1182/blood.V130.Suppl_1.722.722

Published: 2017

Journal Articles

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Abdullah Mahmood Ali, PhD, Yumin Huang, Ronald F Pinheiro, MD, Fumin Xue, PhD, Jingping Hu, PhD, Nicholas Iverson, BS, Daniela Hoehn, MDPhD, Diego Coutinho, BS, Joseph Lane, MD, Christopher D. Hillyer, MD, Naomi Galili, PhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 4244.

https://doi.org/10.1182/blood.V130.Suppl_1.4244.4244

Published: 2017

Journal Articles

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Mark J. Levis, MD, Alexander E. Perl, MD, Jessica K. Altman, MD, Jorge E. Cortes, MD, Catherine C. Smith, MD, Maria R. Baer, MD, David F. Claxton, Joseph G. Jurcic, MD, Ellen K Ritchie, MD, Stephen A Strickland, Raoul Tibes, Jason Hill, PhD, Shufang Liu, Erkut Bahceci, MD

Blood (2017) 130 (Supplement 1): 2705.

https://doi.org/10.1182/blood.V130.Suppl_1.2705.2705

Published: 2017

Journal Articles

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Abdullah Mahmood Ali, PhD, Yumin Huang, Diego Coutinho, BS, Brian Chernak, BA, Etienne De Clara, PhD, Daniela Hoehn, MDPhD, Joseph G. Jurcic, MD, Mohandas Narla, DSc, Xiuli An, MD PhD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 2952.

https://doi.org/10.1182/blood.V130.Suppl_1.2952.2952

Published: 2017

Journal Articles

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Diego Coutinho, BS, Abdullah Mahmood Ali, PhD, Antonio Gualberto, PhD MD, Catherine Scholz, PharmD, Karen Bracken, MHS, Joseph G. Jurcic, MD, Azra Raza, MD

Blood (2017) 130 (Supplement 1): 1677.

https://doi.org/10.1182/blood.V130.Suppl_1.1677.1677

Published: 2017

Journal Articles

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Joseph G. Jurcic, MD, Moshe Yair Levy, MD, Jae H. Park, MD, Farhad Ravandi, MD, Alexander E. Perl, MD, John M. Pagel, MD PhD, B. Douglas Smith, MD, Elihu H. Estey, MD, Hagop Kantarjian, MD, Dragan Cicic, MD, David A. Scheinberg, MD PhD

Blood (2016) 128 (22): 4050.

https://doi.org/10.1182/blood.V128.22.4050.4050

Published: 2016

NARROW

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Minimal Residual Disease Eradication with Venetoclax in Acute Myeloid Leukemia

Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study

Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

A Phase 2 Study of Actinium-225 ( 225 Ac)-Lintuzumab in Older Patients with Previously Untreated Acute Myeloid Leukemia (AML) Unfit for Intensive Chemotherapy

Longitudinal Transcriptome Analysis of Myelodysplatic Syndrome Progression to Acute Myeloid Leukemia: Implications for Prognosis

Preliminary Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

Emergence of a Novel Clinical Entity within Myelodysplastic Syndromes Marked By Absence of Quantifiable Terminal Erythroid Differentiation, More Profound Anemia and Significantly Worse Survival across All Prognostic Risk Categories

Evaluation of the Impact of Minimal Residual Disease, FLT3 Allelic Ratio, and FLT3 Mutation Status on Overall Survival in FLT3 Mutation-Positive Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the Chrysalis Phase 1/2 Study

Unique Gene Expressional Profile Associated with Lack of Quantifiable Terminal Erythroid Differentiation in Myelodysplastic Syndrome Patients

Killer Immunoglobulin-like Receptors (KIR) in Low-Risk Myelodysplastic Syndrome: Genotyping and Gene Expression Evaluation

Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 ( 225 Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only